Back to All Combinations

Left-Sided Primary

Good Prognosis
60.00% Prevalence Level 1 Tumor Location
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
Location
Treatment Implications

Better prognosis. If RAS WT, strongly prefer anti-EGFR.

Recommended Treatments
If RAS WT: Anti-EGFR
If RAS MT: Bevacizumab
Treatments to Avoid

No specific contraindications noted

Study References

CALGB 80405, PARADIGM

Key Statistics
60.00%
Prevalence in CRC
Yes
Targetable
Clinical Notes
Sidedness is independent prognostic factor.
Information

Category: Tumor Location

Evidence Level: Level 1

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.